S
Setsuko K. Chambers
Researcher at University of Arizona
Publications - 158
Citations - 7181
Setsuko K. Chambers is an academic researcher from University of Arizona. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 45, co-authored 153 publications receiving 6016 citations. Previous affiliations of Setsuko K. Chambers include Yale University & University of Rochester.
Papers
More filters
Journal ArticleDOI
The significance of p53 isoform expression in serous ovarian cancer
TL;DR: It is suggested that mutant p53 activity may be counteracted by Δ133p53, which leads to a more favorable prognosis in advanced serous ovarian carcinomas, and novel therapeutic approaches could be built upon these findings.
Journal ArticleDOI
Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
Setsuko K. Chambers,Joseph T. Chambers,Carol A. Davis,E.I. Kohorn,Peter E. Schwartz,M I Lorber,Robert E. Handschumacher,Giuseppe Pizzorno +7 more
TL;DR: The feasibility of delivering IP CsA alone up to doses of 34.6 mg/kg in conjunction with carboplatin, and the sustaining of IP fluid to blood ratios of 1,000:1 is established.
Journal ArticleDOI
Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients
TL;DR: In patients with advanced ovarian cancer, even in the postoperative state, an evaluation of renal function with a calculated creatinine clearance prior to chemotherapy is sufficient.
Journal ArticleDOI
Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer.
Janos L. Tanyi,Hye Sook Chon,Mark A. Morgan,Setsuko K. Chambers,Ernest S. Han,Kristina A. Butler,Carrie L. Langstraat,Matthew A. Powell,Leslie M. Randall,Alexander L. Vahrmeijer,Ira Winer,Robert M. Wenham +11 more
TL;DR: This phase 3 trial of pafolacianine sodium with NIRF imaging met its primary endpoint, intraoperatively identifying additional cancer not planned for resection in a statistically significant number of patients and may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery.
Journal ArticleDOI
Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis
Eugene P. Toy,Nathalie Bonafé,Asim Savlu,Caroline J. Zeiss,Wenxin Zheng,Maryann B. Flick,Setsuko K. Chambers +6 more
TL;DR: This model provides tumors of significant size and organ diversity which retain their phenotype early in tumorigenesis allowing an early endpoint to assess efficacy of novel treatments and modulation of c-fms proto-oncogene expression via oral administration to SCID mice with subsequent correlation to IHC staining.